The rising interest for precise characterization of the tumour immune contexture has recently
brought forward the high potential of RNA sequencing (RNA-seq) in identifying molecular …

Immune checkpoint inhibitors have demonstrated unprecedented clinical activity in a wide
range of cancers. Significant therapeutic responses have recently been observed in patients …

Background Because responses of patients with cancer to immunotherapy can vary in success,
innovative predictors of response to treatment are urgently needed to improve treatment …

High-throughput genomic analyses may improve outcomes in patients with advanced cancers.
MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. …

PD-1 blockade represents a major therapeutic avenue in anticancer immunotherapy.
Delineating mechanisms of secondary resistance to this strategy is increasingly important. Here, …

Background Recommended treatments of patients with advanced biliary tract cancer (aBTC)
are limited to one chemotherapy doublet. Nevertheless, efficacy of treatment …

Background For patients with metastatic rare cancers, treatments are limited. How systematic
tumor sequencing can improve therapeutic possibilities in this population? Patients and …

This study highlights the paucity of standard-of-care markers that explain treatment resistance
and the promise of investigational and hypothetical markers awaiting further validation. It …

Macrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor
immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 …

PURPOSE To facilitate implementation of precision medicine in clinical management of cancer,
the European Society of Medical Oncology proposed in 2018 a new scale to harmonize …